Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

NCT04128683 | Completed Early Phase 1 Results FDA Drug

• 2 other identifiers: 1913485R21MH120475
• Study Type: interventional
• Target: 31
• Locations: 1 country
• Sites: 1

Brief Summary

Anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN has the highest mortality rate among the psychiatric disorders; however, little is known about biomarkers, and no medication has been approved for AN. Many individuals only partially recover, and treatment options, especially for the psychological components of the illness, are not very effective, highlighting the need for more effective treatments. Brain reward pathways have a direct impact on the drive to eat, and a variety of neuroimaging studies have suggested altered reward processing in AN. The neurotransmitter dopamine has a central role in the reward circuitry to drive food approach, and the dynamic interplay between dopamine receptor response and food restriction could have implications for the pathophysiology of AN. Dopamine-related brain function has been studied indirectly using functional magnetic resonance brain imaging (fMRI) and tasks that deliver reward stimuli unexpectedly, that elicit the so-called prediction error (PE) response. Research in AN showed repeatedly altered PE processing suggesting altered dopamine circuit function in the disorder. Dopamine and PE response have also been associated with altered reversal learning, which has important treatment implication for AN as reversal learning is impaired in the disorder and modulation of the dopamine system could improve treatment.

Conditions

Anorexia Nervosa

Outcome Measures

Primary Outcomes (2)

• Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).

  This task measures responsiveness to unexpected stimulus in the dopamine related brain circuitry. Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. 20 percent of stimulus receipt was unexpected, that is there is a mismatch between expectation and outcome. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan.

  The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days

• Measurement of Brain Activation (Measured in Percent Signal Change) During Taste Stimulus Expectation Using Functional Magnetic Resonance Imaging (fMRI).

  Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. Here only stimulus expectation data were analyzed. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan.

  The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days

Study Arms (12)

Healthy Controls, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Healthy Controls, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Healthy Controls, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Healthy Controls, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Healthy Controls, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Healthy Controls, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo

EXPERIMENTAL

Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo

EXPERIMENTAL

Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan)

Drug: amisulpride; Drug: bromocriptine; Drug: Placebo

Interventions

amisulpride DRUG

Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

Also known as: Solian

Anorexia Nervosa, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Anorexia Nervosa, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Anorexia Nervosa, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;; Healthy Controls, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Healthy Controls, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Healthy Controls, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Healthy Controls, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Healthy Controls, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Healthy Controls, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;

bromocriptine DRUG

Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

Also known as: Parlodel

Anorexia Nervosa, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Anorexia Nervosa, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Anorexia Nervosa, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;; Healthy Controls, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Healthy Controls, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Healthy Controls, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Healthy Controls, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Healthy Controls, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Healthy Controls, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;

Placebo DRUG

Placebo pill with no active drug ingredients

Anorexia Nervosa, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Anorexia Nervosa, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Anorexia Nervosa, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Anorexia Nervosa, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;; Healthy Controls, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo; Healthy Controls, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine; Healthy Controls, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo; Healthy Controls, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride; Healthy Controls, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine; Healthy Controls, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride;

Eligibility Criteria

• Age: 18 Years - 29 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Controls
• Females ages 18-29 years
• Healthy body weight between 90 and 110 % average body weight since puberty.
• Regular monthly menstrual cycle
• Edinburgh Handedness Inventory Revised (EHI-R) LQ\* score \> +200
• English is primary language spoken
• Restricting Type Anorexia Nervosa
• Females ages 18-29 years
• Diagnostic criteria. Current diagnosis of AN, including being underweight below 17.5 body mass index (BMI, kg/m2), will have a severe fear of weight gain, body image distortion and absence of the menstrual cycle over three consecutive months.
• First 1-2 weeks in treatment at The University of California San Diego Eating Disorders Center for Treatment and Research or Rady Children's Hospital San Diego Medical Behavioral Unit.
• Restricting subtype, that is without binge/purge behaviors
• Edinburgh Handedness Inventory Revised (EHI-R) LQ\* score \> +200
• English is primary language spoken

You may not qualify if:

• Healthy Controls
• Current pregnancy or breast feeding within last 3 months
• Illiterate/Blind individuals
• First degree relative with current or past eating disorder
• Current Medications other than BCP or IUD
• Contraindications to amisulpride or bromocriptine (as determined through medical history in bioscreen and PI interview) including: Syncopal migraine; Uncontrolled hypertension; Pheochromocytoma; Prolactinoma; Breast cancer; hypersensitivity/allergy to amisulpride or bromocriptine; History of long QT syndrome; Family history of sudden death or long QT syndrome; History of seizures or seizure disorder
• Past or present Axis I psychiatric disorder including substance or alcohol use disorder as determined through SCID-5 clinical interview
• Major Medical illness (as determined through medical history in bioscreen and PI interview) such as:
• o Conditions that are life threatening: cancer heart disease stroke HIV/AIDS
• o Conditions that are life threatening Conditions that cause serious disability without necessarily being life threatening: stroke closed head or spinal cord injuries mental retardation congenital malformations.
• o Conditions that cause significant pain or discomfort that can cause serious interruptions to life activities: severe allergies migraine arthritis sickle cell disease
• o Conditions that require major commitments of time and effort from care-givers for a substantial period of time: mobility disorders blindness Alzheimer's disease and other dementias chronic obstructive pulmonary disease paraplegia or quadriplegia Down's syndrome depression
• o Conditions that may require frequent monitoring: diabetes conditions requiring anticoagulation treatment severe asthma severe allergies schizophrenia and other psychotic illnesses.
• o Conditions that predict or are associated with severe consequences: hypertension (associated with heart disease) depression (associated with suicide) diabetes (associated with blindness, kidney failure) alcohol and other substance abuse (associated with intentional and unintentional injuries).
• Recent history of suspected substance abuse or a lifetime history of psychostimulant abuse and/or dependence

Sponsors & Collaborators

• University of California, San Diego: lead
• National Institute of Mental Health (NIMH): collaborator

Study Sites (1)

University of California San Diego

San Diego, California, 92121, United States

Location

MeSH Terms

Conditions

Anorexia Nervosa

Interventions

Amisulpride; Bromocriptine

Condition Hierarchy (Ancestors)

Feeding and Eating Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Benzamides; Amides; Organic Chemicals; Benzoates; Acids, Carbocyclic; Carboxylic Acids; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Ergotamines; Ergot Alkaloids; Alkaloids; Heterocyclic Compounds; Ergolines; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring

Results Point of Contact

• Title: Dr. Guido Frank
• Organization: University of California San Diego

gfrank@health.ucsd.edu

858-246-2053

Study Officials

• Guido Frank, MD

  University of California, San Diego

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: The participant did not know what medication they were receiving on each scan day.
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: There are two groups in this study, healthy controls and anorexia nervosa. Each group completes 3 MRI scans where one of the following medications are administered 3 hours prior to the start of the scan: placebo, amisulpride, bromocriptine. The order of the medication scans was randomized.

Study Record Dates

• First Submitted: October 14, 2019
• First Posted: October 16, 2019
• Study Start: October 20, 2020
• Primary Completion: September 6, 2023
• Study Completion: January 1, 2025
• Last Updated: April 11, 2025
• Results First Posted: April 11, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)